203 related articles for article (PubMed ID: 21603258)
1. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.
Vishnu P; Roy V
Breast Cancer (Auckl); 2011; 5():53-65. PubMed ID: 21603258
[TBL] [Abstract][Full Text] [Related]
2. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
3. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Megerdichian C; Olimpiadi Y; Hurvitz SA
Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
[TBL] [Abstract][Full Text] [Related]
4. Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety.
Hassan MS; Awasthi N; Ponna S; von Holzen U
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509639
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy evaluation of albumin-bound paclitaxel.
Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
[TBL] [Abstract][Full Text] [Related]
6. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer.
Di Costanzo F; Gasperoni S; Rotella V; Di Costanzo F
Onco Targets Ther; 2009 Feb; 2():179-88. PubMed ID: 20616905
[TBL] [Abstract][Full Text] [Related]
8. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
9. ABI 007.
Drugs R D; 2004; 5(3):155-9. PubMed ID: 15139776
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
Montero AJ; Adams B; Diaz-Montero CM; Glück S
Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.
Yamamoto Y; Kawano I; Iwase H
Onco Targets Ther; 2011; 4():123-36. PubMed ID: 21792318
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
14. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
16. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
Liu M; Liu S; Yang L; Wang S
BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289
[TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.
Dranitsaris G; Yu B; King J; Kaura S; Zhang A
Clinicoecon Outcomes Res; 2015; 7():249-56. PubMed ID: 25999749
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.
Al-Hajeili M; Azmi AS; Choi M
Onco Targets Ther; 2014; 7():187-92. PubMed ID: 24523592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
